CMO taps Capsugel for early-phase supply edge

UK contract manufacturer Molecular Profiles is adding an Xcelodose 1205 powder micro-doser for capsule and vial filling. The purchase furthers the company's goal of expanding into early-phase drug trial supply production.

The Xcelodose unit, made by Pfizer's Capsugel group, provides for dosing of drug materials in quantities as small as 100 micrograms. Such precision is especially beneficial in early-phase trial materials because it eliminates the need for formulation development and stability studies, the company says.

Separately, Capsugel has garnered rights to the FlexTab dosage-form technology. The oral-delivery formulation platform, based on injection-molding technology, follows eight years of collaboration with drug giant GSK.

- see the Molecular Profiles release
- here's the FlexTab announcement

Suggested Articles

In a first, the FDA and Indian oversight agencies worked together to block illegal drugs from entering the U.S. 

After months of delay for ultra-pricey gene therapy Zynteglo, Bluebird Bio is hoping to dose its first German patients in the first half of the year.

North Carolina is providing some financial assistance for the construction of Audentes gene therapy facility in Sanford, North Carolina. (Astellas)